Futura Medical welcomes former Shield Therapeutics FD to the board
Derek Martin has left Futura Medical to pursue other business interests
Company
LON:FUM
Futura Medical specialises in the development and global commercialisation of innovative sexual health products, including lead product Eroxon®. The company's core strength lies in its research, development and commercialisation of topically delivered gel formulations in sexual health products.
303 stories · page 12 of 16
Derek Martin has left Futura Medical to pursue other business interests
Investments and investor services
The minister responsible for Britain's exit from the EU, David Davis said the UK would lead a “global race to the top"
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Some of the main news-driven risers and fallers in London on Thursday...
The Journal of Sexual Medicine is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel
Investments and investor services
If you happen to work for a FTSE 100 company, your boss has already earned more in the past two-and-a-half days then the average UK employee will this year
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Some of the biggest risers and fallers in London on Wednesday
Data from 40 men will determine the doses used in the final-stage clinical assessment MED2002
Investments and investor services
London's blue-chip index closed the day lower but retailers and housebuilders did well, oh, and there was some Brexit news...
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers today in London
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Some of the main news-driven risers and fallers at 3.30pm...
“Futura made excellent progress in the first half of 2017 with MED2002, our breakthrough erectile dysfunction gel, which is moving close to its phase III programme”
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
The agreement, signed in April 2013, covered manufacturing, marketing and distribution rights to CSD500 in North America and certain countries in Europe
Archive
A glance at some of the stories on te Proactive newswire today